Umoja Biopharma: Funding, Investors & Team (Sep 2026)
Umoja Biopharma specializes in cutting-edge immunotherapy that involves modifying T cells in the patient's body to effectively attack cancer. The company provides adaptable treatment plans for solid tumors and blood cancers that traditionally have low response rates to existing therapies. Using their own CAR T-cell gene therapy technology, they seek to enhance patient results at different cancer stages.
Umoja Biopharma has raised $310M across 2 funding rounds on record, the most recent a Series C of $100M announced in Jan 2025.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Umoja Biopharma Company Profile and Key Stats
Latest funding round on record: Jan 2025.
Umoja Biopharma Funding Rounds
Umoja Biopharma raised $210M in an undisclosed round announced in Jun 2021.
3.6 years later, a Series C of $100M was announced in Jan 2025.
Umoja Biopharma Founders and Leadership Team
Contact details for the Umoja Biopharma team: 2 of 2 have an email address on file.
Start 14-day free trial →Umoja Biopharma Funding Compared to Other Biotechnology Startups
Umoja Biopharma's latest round of $100M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Umoja Biopharma in Biotechnology and Seattle
Companies Similar to Umoja Biopharma
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Novir is an emerging diagnostic biotechnology company with an unmatched team of professionals and trusted…
Abcuro’s mission is to develop a new class of immune-modulatory bio-therapeutics for treating both…
Georgiamune Inc. is a privately-owned biotechnology company that specializes in advanced immunotherapy…
Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new…
InduPro is a biotechnology firm that focuses on protein therapeutics and technologies related to cell-surface…
Umoja Biopharma Funding FAQs
What does Umoja Biopharma do?
Umoja Biopharma specializes in cutting-edge immunotherapy that involves modifying T cells in the patient's body to effectively attack cancer. The company provides adaptable treatment plans for solid tumors and blood cancers that traditionally have low response rates to existing therapies. Using their own CAR T-cell gene therapy technology, they seek to enhance patient results at different cancer stages.
How much funding has Umoja Biopharma raised?
Umoja Biopharma has raised $310M across 2 rounds on record. The most recent is a Series C of $100M announced in Jan 2025.
When did Umoja Biopharma last raise funding?
Umoja Biopharma's most recent funding round on record is a Series C of $100M, announced in Jan 2025.
Who founded Umoja Biopharma?
FundedIQ lists Ryan Crisman (Founder) at Umoja Biopharma.
Who is the CEO of Umoja Biopharma?
Andy Scharenberg is listed as CEO at Umoja Biopharma.
Where is Umoja Biopharma headquartered?
Umoja Biopharma is based in Seattle, Washington, United States.
How many employees does Umoja Biopharma have?
Umoja Biopharma is in the 101-250 employee band.
How does Umoja Biopharma's funding compare to other Biotechnology startups?
Umoja Biopharma's latest round of $100M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.
About FundedIQ's Umoja Biopharma Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Umoja Biopharma is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.